- Price
- $64.74
- Day
- +1.98%
- Mkt Cap
- $6.02B
- 52W Range
- $22.06 – $68.73
- Volume
- 1.38M
- Beta
- 1.06
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.Live webcast of the presentation will be accessible on the Investor page of Travere's website at ir.travere.com/events-and-presentations. Replay will be available for up to 30 days following the event.About Travere TherapeuticsAt Travere Therapeutics, we are in rare.
Bank of America Corp DE Invests $259.53 Million in Travere Therapeutics, Inc. $TVTX
Bank of America Corp DE acquired a new stake in shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,568,341 shares of the company's stock, valued at approximately $259,527,000. Bank of America Corp DE
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 56,220 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted a.
Hsbc Holdings PLC Sells 176,242 Shares of Travere Therapeutics, Inc. $TVTX
Hsbc Holdings PLC cut its stake in shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) by 44.4% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 220,611 shares of the company's stock after selling 176,242 shares during the period. Hsbc Holdings PLC